Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma.

IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM

Thyroid Research Pub Date : 2023-01-16 DOI:10.1186/s13044-022-00143-3

Elisa Minaldi, Carlotta Giani, Laura Agate, Eleonora Molinaro, Rossella Elisei

{"title":"Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma.","authors":"Elisa Minaldi, Carlotta Giani, Laura Agate, Eleonora Molinaro, Rossella Elisei","doi":"10.1186/s13044-022-00143-3","DOIUrl":null,"url":null,"abstract":"Background: Currently, surgery alone is the gold standard treatment for minimally invasive follicular thyroid cancer (mi-FTC).Case presentation: A case of a mi-FTC diagnosed in 1994 was treated with total thyroidectomy and radioiodine (RAI) ablation, according to the therapeutic algorithm used at that time. Nevertheless, he had a recurrence with distant metastasis after 24 years from the initial treatment.Conclusion: Total thyroidectomy and RAI ablation might have delayed the development of distant metastasis but they were not sufficient to avoid disease recurrence. Certainly, remnant ablation simplified the follow-up and the monitoring of serum thyroglobulin allowed the early detection of the biochemical recurrence, but didn't change the outcome of the disease. Moreover, because of this early detection the patient was exposed to useless biochemical and imaging examinations. The aim of this report is to discuss the pros and cons of an aggressive treatment of a patient with mi-FTC.","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841632/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13044-022-00143-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Currently, surgery alone is the gold standard treatment for minimally invasive follicular thyroid cancer (mi-FTC).

Case presentation: A case of a mi-FTC diagnosed in 1994 was treated with total thyroidectomy and radioiodine (RAI) ablation, according to the therapeutic algorithm used at that time. Nevertheless, he had a recurrence with distant metastasis after 24 years from the initial treatment.

Conclusion: Total thyroidectomy and RAI ablation might have delayed the development of distant metastasis but they were not sufficient to avoid disease recurrence. Certainly, remnant ablation simplified the follow-up and the monitoring of serum thyroglobulin allowed the early detection of the biochemical recurrence, but didn't change the outcome of the disease. Moreover, because of this early detection the patient was exposed to useless biochemical and imaging examinations. The aim of this report is to discuss the pros and cons of an aggressive treatment of a patient with mi-FTC.

Abstract Image

查看原文本刊更多论文

微创滤泡性甲状腺癌采用手术和放射性碘治疗的利弊。

背景:目前，单纯手术治疗是微创滤泡性甲状腺癌的金标准治疗方法。病例介绍:1994年诊断的半ftc病例，根据当时使用的治疗方法，采用甲状腺全切除术和放射性碘(RAI)消融治疗。然而，他在最初治疗24年后复发并远处转移。结论:甲状腺全切除术和RAI消融可能延缓了远处转移的发展，但不足以避免疾病复发。当然，残余消融简化了随访，血清甲状腺球蛋白的监测可以早期发现生化复发，但不能改变疾病的结局。此外，由于这种早期发现，患者暴露于无用的生化和影像学检查。本报告的目的是讨论积极治疗半ftc患者的利弊。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thyroid Research Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

3.10

自引率

4.50%

发文量

审稿时长

8 weeks